Cargando…

Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer

SIMPLE SUMMARY: Aromatase inhibitors (AIs) remain key elements of endocrine therapy for patients with hormone receptor positive HER2 negative metastatic breast cancer (HR(+) HER2(−) MBC). Recent advances include the use of CDK 4/6 inhibitors or PIK3CA inhibitor in the clinic; however, few immunother...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ge, Xuan, Yost, Susan E., Lee, Jin Sun, Frankel, Paul H., Ruel, Christopher, Cui, Yujie, Murga, Mireya, Tang, Aileen, Martinez, Norma, Chung, Samuel, Yeon, Christina, Stewart, Daphne, Li, Daneng, Rajurkar, Swapnil, Somlo, George, Mortimer, Joanne, Waisman, James, Yuan, Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454514/ https://www.ncbi.nlm.nih.gov/pubmed/36077811 http://dx.doi.org/10.3390/cancers14174279

Ejemplares similares

Phase 2 prospective open label study of neoadjuvant nab‐paclitaxel, trastuzumab, and pertuzumab in patients with HER2‐positive primary breast cancer
por: Lavasani, Sayeh M., et al.
Publicado: (2022)

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
por: Egelston, Colt A., et al.
Publicado: (2023)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer
por: Egelston, Colt, et al.
Publicado: (2021)

Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer
por: Lee, Jin Sun, et al.
Publicado: (2022)

Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer
por: Ge, Xuan, et al.
Publicado: (2023)

Association of Pre‐Chemotherapy Peripheral Blood Pro‐Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2017)

Hyperglycemia and Glycemic Variability Associated with Glucocorticoids in Women without Pre-Existing Diabetes Undergoing Neoadjuvant or Adjuvant Taxane Chemotherapy for Early-Stage Breast Cancer
por: Mahin, Dana, et al.
Publicado: (2023)

Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer
por: Yuan, Yuan, et al.
Publicado: (2017)

CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study
por: Yuan, Yuan, et al.
Publicado: (2023)

Use of HER2-Directed Therapy in Metastatic Breast Cancer and How Community Physicians Collaborate to Improve Care
por: Mortimer, Joanne E., et al.
Publicado: (2020)

Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors
por: Thanopoulou, Eirini, et al.
Publicado: (2014)

A single institution experience with palbociclib toxicity requiring dose modifications
por: Gong, Jun, et al.
Publicado: (2017)

Genomic mutation-driven metastatic breast cancer therapy: a single center experience
por: Yuan, Yuan, et al.
Publicado: (2017)

HER2-targeted antibody–drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia
por: Rainone, Michael, et al.
Publicado: (2023)

Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer
por: Chen, Bihong T., et al.
Publicado: (2018)

Epitope Characterization of an Aromatase Monoclonal Antibody Suitable for the Assessment of Intratumoral Aromatase Activity
por: Hong, Yanyan, et al.
Publicado: (2009)

Correction: Genomic mutation-driven metastatic breast cancer therapy: a single center experience
por: Yuan, Yuan, et al.
Publicado: (2017)

Assessing brain volume changes in older women with breast cancer receiving adjuvant chemotherapy: a brain magnetic resonance imaging pilot study
por: Chen, Bihong T., et al.
Publicado: (2018)

Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
por: Howell, Anthony, et al.
Publicado: (2004)

Strategies to Improve Participation of Older Adults in Cancer Research
por: Liu, Jennifer, et al.
Publicado: (2020)

Short Stature in Chronic Kidney Disease Treated with Growth Hormone and an Aromatase Inhibitor
por: Mendley, Susan R., et al.
Publicado: (2015)

Long-Term Effect of Aromatase Inhibition in Aromatase Excess Syndrome
por: Binder, Gerhard, et al.
Publicado: (2021)

A Case of Isolated Adrenocorticotropic Hormone Deficiency Caused by Pembrolizumab
por: Bekki, Tomoaki, et al.
Publicado: (2020)

A Polymorphism at the 3′-UTR Region of the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor, Anastrozole, in Metastatic Breast Carcinoma
por: Liu, Lei, et al.
Publicado: (2013)

miR-4463 regulates aromatase expression and activity for 17β-estradiol synthesis in response to follicle-stimulating hormone
por: Lee, Su-Yeon, et al.
Publicado: (2020)

Biological effects of stable overexpression of aromatase in human hormone-dependent breast cancer cells.
por: Macaulay, V. M., et al.
Publicado: (1994)

The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer
por: Fabian, C J
Publicado: (2007)

Aromatase Inhibitor-Induced Erythrocytosis in a Patient Undergoing Hormonal Treatment for Breast Cancer
por: Yeruva, Sri Lakshmi Hyndavi, et al.
Publicado: (2015)

Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis
por: He, Ting-Fang, et al.
Publicado: (2020)

Sequencing of aromatase inhibitors
por: Bertelli, G
Publicado: (2005)

Modulation of Aromatase by Phytoestrogens
por: Lephart, Edwin D.
Publicado: (2015)

Aromatase in the Human Brain
por: Azcoitia, Iñigo, et al.
Publicado: (2021)

Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates
por: Wood, Paul M, et al.
Publicado: (2011)

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer
por: Lee, Jin Sun, et al.
Publicado: (2019)

The Effect of Metalloestrogens on the Effectiveness of Aromatase Inhibitors in a Hormone-Dependent Breast Cancer Cell Model
por: Boszkiewicz, Kamila, et al.
Publicado: (2023)

Letrozole, an aromatase inhibitor, improves seminal parameters and hormonal profile in aged endangered Markhoz bucks
por: Rezaei, Ako, et al.
Publicado: (2022)

Sentinel lymph node B cells can predict disease-free survival in breast cancer patients
por: Blenman, Kim R. M., et al.
Publicado: (2018)

Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase-Inhibitor-Resistant Breast Cancer Cells through the Induction of Apoptosis
por: Walker, Rashidra R., et al.
Publicado: (2022)

Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer
por: Yuan, Yuan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_eekefnhboivqid65qk9m2dr8cr